Sylacauga Health Care Authority INC

Sylacauga Health Care Authority INC was paid $4.15M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 99285, emergency room visit (most serious) — 24% of everything it billed.

33Billing provider infoSYLACAUGA HEALTH CARE AUTHORITY INC
SYLACAUGA, AL 35150

33aNPI1972527265assigned 07/27/2006

33bProvider typeRural Acute Care Hospital

28Total paid$4.15M

24GClaims156,103

24DCodes billed78

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Rural Acute Care Hospital providers in Alabama

Rank by total paid#2 of 11

Median peer was paid$1.34M

This provider vs. median3.1×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	29,811	$472K
2019	21,083	$486K
2020	14,110	$318K
2021	16,773	$491K
2022	25,284	$718K
2023	28,813	$969K
2024incomplete	20,229	$699K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	24%	3,691	3,268	$989K
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	22%	24,711	21,285	$931K
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	21%	14,722	12,547	$865K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	7.3%	6,513	6,207	$303K
80053	Comprehensive metabolic panel	2.8%	11,060	9,632	$117K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.6%	13,080	11,332	$109K
99282	Emergency department visit for the evaluation and management, low to moderate severity	2.5%	2,649	2,452	$103K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	2.5%	6,593	5,825	$102K
87400		2.1%	16,633	7,025	$86K
70450	Computed tomography, head or brain; without contrast material	1.3%	795	606	$54K
69436	Tympanostomy (requiring insertion of ventilating tube), general anesthesia	1.1%	301	151	$47K
70551	Magnetic resonance imaging, brain; without contrast material	1.1%	225	210	$44K

66 more codes

74177	Computed tomography, abdomen and pelvis; with contrast material	1.0%	250	$42K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	3,400	$35K
J1750	Injection, iron dextran, 50 mg	<1%	160	$32K
87081		<1%	2,968	$31K
81001		<1%	7,361	$28K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	161	$25K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	508	$21K
70544		<1%	75	$20K
86756		<1%	876	$19K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	504	$18K
81025		<1%	4,044	$14K
87088		<1%	1,414	$13K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	188	$11K
84484		<1%	1,188	$9K
83690		<1%	1,327	$9K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	36	$8K
80048	Basic metabolic panel (calcium, ionized)	<1%	956	$8K
0001A		<1%	200	$7K
0002A		<1%	171	$6K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	589	$5K
82150		<1%	635	$4K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	3,693	$4K
97597		<1%	264	$4K
59025	Fetal non-stress test	<1%	767	$4K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	1,281	$3K
81003		<1%	1,017	$3K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	20	$3K
72141		<1%	13	$2K
80076		<1%	288	$2K
87106		<1%	208	$2K
83735		<1%	176	$1K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	429	$1K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	4,578	$1K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	805	$1K
0003A		<1%	29	$1K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	2,472	$587.11
82550		<1%	174	$528.00
82553		<1%	70	$527.31
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	7,288	$525.81
86140		<1%	192	$375.16
71046	Radiologic examination, chest; 2 views	<1%	27	$305.75
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	185	$272.89
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	57	$259.75
85610		<1%	52	$224.37
87186		<1%	32	$210.80
83605		<1%	19	$168.15
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	384	$140.98
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	155	$95.29
85730		<1%	37	$93.05
J7050	Infusion, normal saline solution, 250 cc	<1%	128	$58.65
96375	Therapeutic injection; each additional sequential IV push	<1%	1,004	$34.00
J7120	Ringers lactate infusion, up to 1000 cc	<1%	58	$22.05
71045	Radiologic examination, chest; single view	<1%	14	$19.86
J7030	Infusion, normal saline solution , 1000 cc	<1%	661	$10.38
J0690	Injection, cefazolin sodium, 500 mg	<1%	14	$3.08
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	120	$0.98
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	0%	13	$0.00
96376		0%	222	$0.00
36415	Collection of venous blood by venipuncture	0%	716	$0.00
99213	Doctor's office visit, returning patient (routine)	0%	13	$0.00
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	0%	179	$0.00
82962		0%	34	$0.00
96361	Intravenous infusion, hydration; each additional hour	0%	37	$0.00
94760		0%	117	$0.00
J2704	Injection, propofol, 10 mg	0%	61	$0.00
94761		0%	16	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSISK, GLENN (CEO)